RxDoctor Payments DataLook up a doctor →

Philip Mease, MD

Rheumatology · Seattle, WANPI 1336218171

Payments from drug & device makers

$5,085,956in general payments, 2019–2025

Across 2,767 payments — averaging $1838.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$1.3M
  • AbbVie$521K
  • Amgen$466K
  • Janssen Scientific Affairs, LLC$393K
  • Novartis$388K
  • Lilly USA, LLC$315K
  • plus $1.7M from 53 others
$297,984in research payments, 2019–2025

Across 207 payments — averaging $1439.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$129K
  • Pfizer$76K
  • UCB, Inc.$43K
  • Amgen$24K
  • Novartis Pharma AG$12K
  • Bristol Myers Squibb$4K
  • plus $10K from 5 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.129$1,297,113
AbbVie470$521,088
Amgen(2 entities)273$465,945
Janssen Scientific Affairs, LLC256$392,608
Novartis338$388,459
Lilly USA, LLC177$314,650
UCB SA84$302,935
Janssen Research & Development, LLC45$222,046
Pfizer200$202,503
UCB, Inc.196$171,759
Bristol Myers Squibb46$158,910
Eli Lilly52$138,489
Johnson & Johnson121$89,123
Novartis Pharma AG42$75,622
Sun Pharmaceutical Industries Inc.44$72,174
AstraZeneca(2 entities)14$62,265
Takeda Pharmaceuticals U.S.A., Inc.24$47,755
GSK73$46,817
Gilead6$40,486
UCB Biosciences Inc.16$17,746
UCB GmbH3$16,863
Janssen Global Services, LLC5$9,263
Sanofi32$4,869
Regeneron Healthcare Solutions, Inc.15$4,469
Aurinia Pharma U.S., Inc.5$2,588
Mylan Specialty L.p.1$2,500
Argenx US, Inc.1$2,500
CSL Behring1$2,168
Genentech USA, Inc.17$2,105
Jubilant Draximage Inc.1$2,000
Vertex4$1,908
Merck3$1,670
Astrazeneca UK Limited1$1,500
Genentech, Inc.19$851
Samsung Bioepis Co., Ltd.1$700
Assertio Therapeutics, Inc.1$201
Sobi, Inc7$157
Mallinckrodt Enterprises LLC6$124
Biogen1$112
Boehringer Ingelheim Pharma GmbH & Co.kg1$76
Fresenius Kabi USA, LLC3$75
Tersera Therapeutics LLC3$74
Boehringer Ingelheim4$74
Kiniksa Pharmaceuticals, Ltd.3$71
Organon3$69
Radius Health, Inc.3$64
Kiniksa Pharmaceuticals International, PLC2$56
Bioventus LLC2$53
Arcutis Biotherapeutics, Inc.2$50
Pacira Therapeutics, Inc.2$36
Oxford Immunotec USA Inc1$35
Octapharma USA, Inc.1$28
Kyowa Kirin, Inc.1$25
Mallinckrodt Hospital Products Inc.1$25
Ferring Pharmaceuticals Inc.1$25
Ultragenyx Pharmaceutical Inc.1$24
Medexus Pharma, Inc.1$21
Antares Pharma, Inc.1$19
Hikma Pharmaceuticals USA1$15

How this compares

$5,085,956 in reported general payments places this provider in the 95th percentile of 157 rheumatology providers in Washington.

See all rheumatology providers in Washington →

Medicare billing

Part B allowed, 2024
$97,506
Medicare patients
65
Services billed
8,969

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other rheumatology in Seattle

See the full list for Washington →

Where these figures come from

Is this you, or does something look wrong? →